<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03750643</url>
  </required_header>
  <id_info>
    <org_study_id>17090</org_study_id>
    <secondary_id>J1B-MC-FRCC</secondary_id>
    <nct_id>NCT03750643</nct_id>
  </id_info>
  <brief_title>A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis</brief_title>
  <official_title>Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the safety, tolerability, and efficacy of&#xD;
      the study drug known as LY3454738 in healthy participants and participants with atopic&#xD;
      dermatitis. The study has three parts. Each participant will enroll in one part. The study&#xD;
      will last 12 to 24 weeks, depending on part.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Actual">September 7, 2021</completion_date>
  <primary_completion_date type="Actual">September 7, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving a Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 or 1 with a ≥ 2-point Improvement from Baseline</measure>
    <time_frame>Week 12</time_frame>
    <description>The vIGA-AD measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) of LY3454738</measure>
    <time_frame>Day 1 through Day 85 (Day 99 for Part C)</time_frame>
    <description>Cmax of LY3454738</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Versus-Time Curve (AUC) of LY3454738</measure>
    <time_frame>Day 1 through Day 85 (Day 99 for Part C)</time_frame>
    <description>AUC of LY3454738</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>LY3454738 - Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3454738 - Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3454738 administered IV to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV to healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3454738 - Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3454738 administered IV to participants with atopic dermatitis (AD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV to participants with AD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3454738</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3454738 - Part A</arm_group_label>
    <arm_group_label>LY3454738 - Part B</arm_group_label>
    <arm_group_label>LY3454738 - Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3454738</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3454738 - Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo - Part A</arm_group_label>
    <arm_group_label>Placebo - Part B</arm_group_label>
    <arm_group_label>Placebo - Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All: Must have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²),&#xD;
             inclusive, for Parts A and B, and 18.0 to 45.0 kg/m², inclusive, for Part C and a&#xD;
             minimum body weight of 50 kilograms&#xD;
&#xD;
          -  For PART A and B only, regarding the inclusion of healthy Japanese participants:&#xD;
             Minimum age is 20 years and the participant's biological parents and all of the&#xD;
             participant's biological grandparents must be of exclusive Japanese descent and must&#xD;
             have been born in Japan&#xD;
&#xD;
          -  AD:&#xD;
&#xD;
               -  Must have a diagnosis of AD for at least 12 months with either poor response to&#xD;
                  topical treatments or inability to use topical treatments&#xD;
&#xD;
               -  Must agree to use moisturizer daily throughout the treatment period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All: must not have previously completed a clinical trial with a molecule targeting&#xD;
             interleukin-33 (IL-33) or its receptor&#xD;
&#xD;
          -  AD:&#xD;
&#xD;
               -  Must not have received certain topical medications for AD within 2 weeks prior to&#xD;
                  randomization&#xD;
&#xD;
               -  Must not have received certain oral medications for AD or received phototherapy&#xD;
                  within 4 weeks prior to randomization&#xD;
&#xD;
               -  Must not have received any antibody-based biologic agents (marketed or&#xD;
                  investigational) within 5 half lives (t1/2) of the drug prior to randomization&#xD;
&#xD;
               -  Must not have received intravenous, intramuscular, or intra-articular steroids in&#xD;
                  the past 6 weeks prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Research Trials, LLC</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Arkansas Clinical Trials Center</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revival Research Corporation</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Health Research Center</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613-1244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Sciences, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAREXEL-Phase 1 Baltimore Harbor Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JUVA Skin &amp; Laser Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022-3350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wright State Physicians Dermatology</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>46435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology</name>
      <address>
        <city>Los Prados</city>
        <zip>00727</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group, PSC - Hato Rey Site</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Poland</country>
  </removed_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/1FiRtIYceUkw4QOKAMusai</url>
    <description>A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis (Eczema)</description>
  </link>
  <verification_date>October 1, 2021</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

